Literature DB >> 21180592

Current trends in inflammatory bowel disease: the natural history.

Ebbe Langholz1.   

Abstract

The description of the prognosis of inflammatory bowel disease (IBD) is based on systematic follow-up of population-based cohorts. A steady increase in incidence of IBD has occurred. The distribution of ulcerative colitis (UC) is fairly uniform with a preponderance of left-sided disease. One-third of Crohn's disease (CD) patients present with colonic disease, one-third with ileocolonic disease and one-third with small bowel disease. IBD is associated with extra-intestinal manifestations (EIMs) in up to 36% of patients. Uveitis and episcleritis are the most common. The cumulative probability of a relapsing course in UC is 90% after 25 years. In CD disease behaviour varies substantially with time. At diagnosis behaviour is inflammatory in 70% of patients. At follow-up there is a change to either stricturing or penetrating disease. Most patients with CD will eventually require surgery. Risk factors for CD recurrence after surgery include penetrating/fistulizing disease behaviour, young age, short duration of disease before first surgery and ileocolonic disease. The incidence of colorectal cancer (CRC) in UC seems to be decreasing. The risk of CRC in CD seems to be equivalent to the risk in UC. Patients with small bowel CD are also at increased risk of small bowel adenocarcinoma. CD is associated with a mortality rate 20-70% higher than expected, whereas mortality in UC is equivalent to that of the general population. The improved prognosis of IBD, especially UC, could be due to a chemopreventive effect of the medications used. Further studies are needed to develop the best strategy for the reduction of mortality and cancer risk in IBD.

Entities:  

Keywords:  colorectal cancer; disease course; epidemiology; inflammatory bowel disease; mortality; prognosis

Year:  2010        PMID: 21180592      PMCID: PMC3002570          DOI: 10.1177/1756283X10361304

Source DB:  PubMed          Journal:  Therap Adv Gastroenterol        ISSN: 1756-283X            Impact factor:   4.409


  61 in total

1.  Changes in extent of ulcerative colitis: a study on the course and prognostic factors.

Authors:  E Langholz; P Munkholm; M Davidsen; O H Nielsen; V Binder
Journal:  Scand J Gastroenterol       Date:  1996-03       Impact factor: 2.423

2.  Low mortality in ulcerative colitis and Crohn's disease in three regional centers in England.

Authors:  F Farrokhyar; E T Swarbrick; R H Grace; M D Hellier; A E Gent; E J Irvine
Journal:  Am J Gastroenterol       Date:  2001-02       Impact factor: 10.864

3.  Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms.

Authors:  A J Greenstein; P Lachman; D B Sachar; J Springhorn; T Heimann; H D Janowitz; A H Aufses
Journal:  Gut       Date:  1988-05       Impact factor: 23.059

Review 4.  The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review.

Authors:  E V Loftus; P Schoenfeld; W J Sandborn
Journal:  Aliment Pharmacol Ther       Date:  2002-01       Impact factor: 8.171

5.  Crohn's disease in Stockholm County during 1990-2001: an epidemiological update.

Authors:  Annika Lapidus
Journal:  World J Gastroenterol       Date:  2006-01-07       Impact factor: 5.742

6.  Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis.

Authors:  Matthew D Rutter; Brian P Saunders; Kay H Wilkinson; Steve Rumbles; Gillian Schofield; Michael A Kamm; Christopher B Williams; Ashley B Price; Ian C Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

7.  Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County.

Authors:  Karen Vanessa Winther; Tine Jess; Ebbe Langholz; Pia Munkholm; Vibeke Binder
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

8.  Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.

Authors:  Fabian Schnitzler; Herma Fidder; Marc Ferrante; Maja Noman; Ingrid Arijs; Gert Van Assche; Ilse Hoffman; Kristel Van Steen; Séverine Vermeire; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2009-09       Impact factor: 5.325

9.  Divergent patterns of total and cancer mortality in ulcerative colitis and Crohn's disease patients: the Florence IBD study 1978-2001.

Authors:  G Masala; S Bagnoli; M Ceroti; C Saieva; G Trallori; I Zanna; G D'Albasio; D Palli
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

10.  Risk factors for early postoperative recurrence of Crohn's disease.

Authors:  E Lautenbach; J A Berlin; G R Lichtenstein
Journal:  Gastroenterology       Date:  1998-08       Impact factor: 22.682

View more
  22 in total

1.  Impact of smoking on disease phenotype and postoperative outcomes for Crohn's disease patients undergoing surgery.

Authors:  Myles R Joyce; Christine D Hannaway; Scott A Strong; Victor W Fazio; Ravi P Kiran
Journal:  Langenbecks Arch Surg       Date:  2011-10-22       Impact factor: 3.445

Review 2.  Have genomic discoveries in inflammatory bowel disease translated into clinical progress?

Authors:  Adam V Weizman; Mark S Silverberg
Journal:  Curr Gastroenterol Rep       Date:  2012-04

3.  Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study.

Authors:  Steven J Edwards; Samantha Barton; Mariana Bacelar; Charlotta Karner; Peter Cain; Victoria Wakefield; Gemma Marceniuk
Journal:  Health Technol Assess       Date:  2021-03       Impact factor: 4.014

Review 4.  A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy.

Authors:  Sherman Picardo; Cynthia H Seow
Journal:  Drugs       Date:  2019-07       Impact factor: 9.546

5.  Adherence to an elemental diet for preventing postoperative recurrence of Crohn's disease.

Authors:  Nobuyoshi Ohara; Tsunekazu Mizushima; Hideki Iijima; Hidekazu Takahashi; Satoshi Hiyama; Naotsugu Haraguchi; Takahiro Inoue; Junichi Nishimura; Shinichiro Shinzaki; Taishi Hata; Chu Matsuda; Hirofumi Yamamoto; Yuichiro Doki; Masaki Mori
Journal:  Surg Today       Date:  2017-05-22       Impact factor: 2.549

6.  Management of iatrogenic perforation during colonoscopy in ulcerative colitis patients: a survey of gastroenterologists and colorectal surgeons.

Authors:  David DiCaprio; Steven Lee-Kong; Guillaume Stoffels; Bo Shen; Ahmed Al-Mazrou; R P Kiran; Burton Korelitz; Arun Swaminath
Journal:  Int J Colorectal Dis       Date:  2018-07-05       Impact factor: 2.571

Review 7.  Risk factors and implications of anastomotic complications after surgery for Crohn's disease.

Authors:  Kristen T Crowell; Evangelos Messaris
Journal:  World J Gastrointest Surg       Date:  2015-10-27

Review 8.  Natural and synthetic polymer-based smart biomaterials for management of ulcerative colitis: a review of recent developments and future prospects.

Authors:  Muhammad Sohail; Muhammad Usman Minhas; Shahzeb Khan; Zahid Hussain; Marcel de Matas; Syed Ahmed Shah; Samiullah Khan; Mubeen Kousar; Kaleem Ullah
Journal:  Drug Deliv Transl Res       Date:  2019-04       Impact factor: 4.617

Review 9.  Pregnancy and inflammatory bowel diseases: Current perspectives, risks and patient management.

Authors:  Pegah Hosseini-Carroll; Monica Mutyala; Abhishek Seth; Shaheen Nageeb; Demiana Soliman; Moheb Boktor; Ankur Sheth; Jonathon Chapman; James Morris; Paul Jordan; Kenneth Manas; Felix Becker; Jonathan Steven Alexander
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

10.  Differential Expression of microRNAs in Peripheral Blood Mononuclear Cells Identifies Autophagy and TGF-Beta-Related Signatures Aberrantly Expressed in Inflammatory Bowel Disease.

Authors:  Aylia Mohammadi; Orlaith B Kelly; Melissa Filice; Boyko Kabakchiev; Michelle I Smith; Mark S Silverberg
Journal:  J Crohns Colitis       Date:  2018-04-27       Impact factor: 9.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.